{"podcast":{"title":"Capital Ideas podcast","slug":"capital-ideas-podcast-325910","podcast_index_feed_id":325910,"rss_url":"https://capitalideas.libsyn.com/rss","website_url":"https://www.capitalgroup.com/advisor/insights/podcast.html","image_url":"https://static.libsyn.com/p/assets/7/e/e/1/7ee1e434042e2b4a16c3140a3186d450/CI_Podcast_KeyArt_Primary-3000x3000-for-libsyn-20260211-80ulv59vv5.jpg","author":"Capital Group","episode_count":328,"summary":"Want to learn how professional investors do it? The Capital Ideas podcast brings you the latest investment thinking from Capital Group, one of the world's largest investment management organizations. Each week we'll get inside the minds of portfolio managers, analysts and economists to break down market trends, macroeconomic forces, investing approaches and lessons learned from personal experience. Take 30 minutes and tap into the intellectual capital of Capital Group. Capital Client Group, Inc. All Capital Group trademarks mentioned are owned by The Capital Group Companies, Inc., an affiliated company or fund. All other company and product names mentioned are the property of their respective companies. For full disclosures go to capitalgroup.com/global-disclosures.","last_synced_at":"2026-06-12T00:19:56.933059+00:00","page_url":"https://stenobird.com/podcast/capital-ideas-podcast-325910"},"episode":{"title":"From medicine to markets: Long-term biotech investing","slug":"from-medicine-to-markets-long-term-biotech-investing","published_at":"2026-05-14T12:00:00+00:00","page_url":"https://stenobird.com/podcast/capital-ideas-podcast-325910/from-medicine-to-markets-long-term-biotech-investing","show_page_url":"https://stenobird.com/podcast/capital-ideas-podcast-325910","url":"https://www.capitalgroup.com/global-disclosures.html","audio_url":"https://traffic.libsyn.com/secure/capitalideas/CapGroup_eps_331_Capital_Conversations_-_Judith_Finegold_FINAL.mp3?dest-id=473267","summary":"Biotech investing often hinges on understanding science, trials and patient outcomes. Dr. Judith Finegold is a physician turned equity analyst, and she explains how her clinical experience helps assess drug pipelines, clinical trials and long term risk in biotech investing — well beyond the headlines. #CapGroupGlobal This content is intended to highlight issues and be of a general nature. It should not be considered advice, an endorsement or a recommendation. Products mentioned are not an offer of the product and may not be available for sale or purchase in all countries. All investments have risk, and you may lose money. Past results are not a guarantee of future results. Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This content is published by Capital Client Group, Inc., and copyrighted to Capital Group and affiliates, 2026, all rights reserved. For more information, including our detailed disclosures, visit www.capitalgroup.com/global-disclosures For our latest insights, practice management ideas and more, subscribe to Capital Ideas at getcapitalideas.com . If you're based outside of the U.S., visit capitalgroup.com for Capital Group insights. Watch our latest podcast, Conversations with Mike Gitlin, on YouTube: https://bit.ly/4aKcZ2c U.K. investors can view a glossary of technical terms here: https://bit.ly/46s4Fmp To stay informed, follow us LinkedIn: https://bit.ly/4qQrPdH YouTube: https://bit.ly/3OJfg6m Follow Mike Gitlin: https://bit.ly/46onTta About Capital Group Capital Group was established in 1931 in Los Angeles, California, with the mission to improve people's lives through successful investing. With our clients at th…","meta_description":"Biotech investing often hinges on understanding science, trials and patient outcomes. Dr. Judith Finegold is a physician turned equity analyst, and she ex…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1231,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/capital-ideas-podcast-325910/episodes/from-medicine-to-markets-long-term-biotech-investing/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/capital-ideas-podcast-325910/from-medicine-to-markets-long-term-biotech-investing.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}